Combined chemotherapy/immunotherapy with TLR3 agonists using ventral water derived exosomes carrying tumor-associated antigens activates and amplifies antigen-specific T cell immunotherapy mechanisms against tumor-induced immunosuppression in advanced ovarian cancer (279). Here, TLR3 is linked to ovarian carcinoma.